VYRIAD INC
Engineered viral vectors for in vivo gene therapy, genome editing, and oncolytic immunotherapy
New patent ·
- Sector
- Biotech
- Headquarters
- Rochester, MN
- Latest Form D
- $24.4M, Nov 2019
- Total capital
- $30.2M
- Federal grants
- $5.8M
- 8 awards · 2017–2020
- Rank in peer group#101 of 326
- Private capital raised
- $24.4M
- 1 Form D · last Nov 2019
- 83 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 31 pending · first 2026
- Rank in peer group#58 of 326
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumors$824K
- Private capital raisedForm D · SEC · 1st filing$24.4M
- Federal grantHealth and Human S · Phase II · Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumors$1.8M
- Federal grantHealth and Human S · Phase II · Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumors$950K
- Federal grantHealth and Human S · Phase II · Intravesical Oncolytic Therapy For Bladder Cancer$909K
- Federal grantHealth and Human S · Phase II · Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumors$108K
- Federal grantHealth and Human S · Phase II · Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumors$179K
Show 2 earlier federal awards
- Federal grantHealth and Human S · Phase II · Intravesical Oncolytic Therapy For Bladder Cancer$925K
- Federal grantHealth and Human S · Phase II · Intravesical Oncolytic Therapy For Bladder Cancer$157K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
26months
from VYRIAD INC’s first federal award to its first private round.
- First federal award · Sep 2017
- Health and Human S · $157K
- First Form D · Nov 2019
- $24.4M · 1st Form D
- Awards before first raise
- 7 awards
An association in public records, not a cause or a prediction.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#101 · top 31%
- Granted patents#58 · top 18%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Ahryon N. ChoDirectorNamed in SEC Form D filings
- Alice S. Bexon, MDExecutive OfficerNamed in SEC Form D filings
- Andrew N. KhooDirectorNamed in SEC Form D filings
- Edwin M. Kania, Jr.DirectorNamed in SEC Form D filings
- Glen N. BarberDirector, PromoterNamed in SEC Form D filings
- James J. HannonExecutive OfficerNamed in SEC Form D filings
Show all 9 people
- Kah-Whye S. Peng, PhDExecutive OfficerNamed in SEC Form D filings
- Nathan L. StacyDirectorNamed in SEC Form D filings
- Stephen J. Russell, MD, PhDExecutive Officer, Director, PromoterNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 33- New patentIFNbeta as a Pharmacodynamic Marker in VSV-IFNbeta-NIS Oncolytic TherapyUSPTOUS 12,754,182
- GrantedDetection Assays For Coronavirus Neutralizing AntibodiesUSPTOUS 12,529,699
- PendingModified Rhabdovirus Glycoproteins And Uses ThereofUSPTOApplication 19151008
Show all 33 patent records
- IFNbeta as a Pharmacodynamic Marker in VSV-IFNbeta-NIS Oncolytic TherapyOct 6, 2026 · US 12,754,182Granted
- Detection Assays For Coronavirus Neutralizing AntibodiesJan 20, 2026 · US 12,529,699Granted
- Modified Rhabdovirus Glycoproteins And Uses ThereofNov 6, 2025 · Application 19151008Pending
- Combinations Of Checkpoint Inhibitors And Oncolytic Virus For Treating CancerMay 15, 2025 · Application 18839107Pending
- IFNbeta as a Pharmacodynamic Marker in VSV-IFNbeta-NIS Oncolytic TherapyJun 9, 2022 · Application 17598510Pending
- Modified Rhabdovirus Glycoproteins And Uses ThereofApplication 63466931Pending
- Methods And Materials For Treating CancerApplication 63464417Pending
- Modified Rhabdovirus Glycoproteins And Uses ThereofApplication 63481847Pending
- Combination Of Checkpoint Inhibitors And An Oncolytic Virus For Treating CancerApplication PCTUS2022073845Pending
- Combination Of Checkpoint Inhibitors And An Oncolytic Virus For Treating CancerApplication 63365288Pending
- Combination Of Checkpoint Inhibitors And An Oncolytic Virus For Treating CancerApplication 63268139Pending
- Detection Assays For Coronavirus Neutralizing AntibodiesApplication PCTUS2021027909Pending
- Methods And Materials For Treating CancerApplication 19479870Pending
- Detection Assays For Coronavirus Neutralizing AntibodiesApplication 63151623Pending
- Compositions For Treating And/or Preventing Coronavirus InfectionsApplication 63129081Pending
- Compositions For Treating And/or Preventing Coronavirus InfectionsApplication 63078839Pending
- Detection Assays For Coronavirus Neutralizing AntibodiesApplication 63078214Pending
- Compositions For Treating And/or Preventing Coronavirus InfectionsApplication 63065896Pending
- Compositions For Treating And/or Preventing Coronavirus InfectionsApplication 63059325Pending
- Compositions For Treating And/or Preventing Coronavirus InfectionsApplication 63040470Pending
- Detection Assays For Coronavirus Neutralizing AntibodiesApplication 63029267Pending
- Methods And Materials For Treating CancerApplication 63763599Pending
- Detection Assays For Coronavirus Neutralizing AntibodiesApplication 63020445Pending
- Detection Assays For Coronavirus Neutralizing AntibodiesApplication 63012074Pending
- Detection Assays For Coronavirus Neutralizing AntibodiesApplication 63012066Pending
- Compositions For Treating And/or Preventing Coronavirus InfectionsApplication 63012070Pending
- Ifnbeta As A Pharmacodynamic Marker In Vsv-ifnbeta-nis Oncolytic TherapyApplication PCTUS2020025409Pending
- Varicella-zoster Viruses And Methods And Materials For Using Varicella-zoster VirusesApplication 19623838Pending
- Compositions For Treating And/or Preventing Coronavirus InfectionsApplication 63151279Pending
- Recombinant Rhabdovirus Encoding INTERLEUKIN-12 (IL-12)Application 63660073Pending
- Recombinant Rhabdovirus Encoding INTERLEUKIN-12 (IL-12)Application 63570881Pending
- Varicella-zoster Viruses And Methods And Materials For Using Varicella-zoster VirusesApplication 63567250Pending
- Modified Rhabdovirus Glycoproteins And Uses ThereofApplication 63597831Pending
Related companies, and why
- CorxelSimilar federal contract value in Biotech · null in contracts
- CAPTOZYME, INC.Similar federal contract value in Biotech · null in contracts
- NANODESK, LLCSimilar federal contract value in Biotech · null in contracts
- Synoxa Sciences, IncSimilar federal contract value in Biotech · null in contracts
- PEARL SCIENTIFIC LLCSimilar federal contract value in Biotech · null in contracts
- CytomX TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .